Skip to main content
v2026.11,986 entries · CC-BY 4.0

Framingham Risk Score: 10-Year CVD Equations, Cox Regression & EHR Calculation

Biostatistical guide to the Framingham Risk Score (Wilson 1998 and D’Agostino 2008), Cox proportional hazards equations, ATP III thresholds, and EHR CDS.

Written and maintained by CASRAI Editorial Board

Published · Last updated

On this page

The Framingham Risk Score (FRS) is a multivariable, sex-specific clinical prediction algorithm developed from longitudinal cohort data in the Framingham Heart Study to estimate the 10-year probability of incident cardiovascular events in adults without pre-existing cardiovascular disease. First formalized for coronary heart disease (CHD) by Wilson et al. in Circulation (1998) and expanded to a composite general cardiovascular disease (CVD) endpoint by D’Agostino et al. in Circulation (2008), the Framingham Risk Score serves as a benchmark model in cardiovascular epidemiology, preventive cardiology trials, and biostatistical calibration studies alongside newer calculators such as the ASCVD Risk Estimator and acute care tools like the HEART Score.

What Is the Framingham Risk Score and How Is It Used in Clinical Research and Healthcare?

In both primary care prevention and clinical trial eligibility screening, the Framingham Risk Score translates continuous and categorical patient risk factors into an absolute 10-year event probability. Two landmark formulations are widely cited in peer-reviewed research and clinical guidelines:

  • 1998 Hard CHD / Total CHD Model (Wilson et al., Circulation 1998;97:1837–1847): Derived from 2,489 men and 2,856 women aged 30 to 74 years from the Framingham Original and Offspring cohorts followed for 12 years. The NCEP Adult Treatment Panel III (ATP III) adapted this model to predict 10-year “hard CHD” (myocardial infarction and coronary death).
  • 2008 General CVD Risk Profile (D’Agostino et al., Circulation 2008;117:743–753, PMC2719252): Derived from 8,491 Framingham participants (3,969 men and 4,522 women) aged 30 to 74 years free of CVD at baseline, during which 1,174 participants developed a first CVD event over 12 years of follow-up. The composite outcome encompasses coronary death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke, transient ischemic attack, peripheral artery disease, and heart failure.

Mathematical Formulation and Predictor Variables

Rather than relying solely on integer point tables, clinical informatics systems and research pipelines compute the continuous Framingham Risk Score using a sex-specific Cox proportional hazards regression equation:

P(10-year CVD) = 1 - S_0(10) ^ exp( Sum[ beta_i * X_i ] - Sum[ beta_i * X_mean_i ] )

In the 2008 D’Agostino laboratory-based model, the continuous predictors are natural-log transformed (ln(Age), ln(Total Cholesterol), ln(HDL-C), and ln(Systolic Blood Pressure) stratified by whether hypertension is treated or untreated) and combined with binary indicators for current cigarette smoking and diabetes mellitus. In the 2008 model, the 10-year baseline survival probability S_0(10) is 0.88936 for men and 0.95012 for women, yielding C-statistics (discrimination) of 0.763 in men and 0.793 in women. A parallel non-laboratory office-based version substitutes ln(Body Mass Index) for total and HDL cholesterol when lipid panels are unavailable.

What Standards or Regulatory Requirements Govern the Framingham Risk Score?

Clinical guidelines and methodological validation standards define how the Framingham Risk Score is categorized, calibrated, and reported in clinical research:

Guideline / Standard Risk Categorization & Methodological Rule Research & Clinical Application
NHLBI NCEP ATP III (2001/2002) 10-year hard CHD risk <10% (Low Risk), 10%–20% (Intermediate Risk), >20% (High Risk / CHD Risk Equivalent) Stratifying asymptomatic participants in lipid-lowering trials and preventive cardiology cohorts
2008 General CVD Thresholds (D’Agostino et al.) Broad composite CVD endpoint typically categorized as <10% (Low), 10%–20% (Intermediate), and >20% (High) Evaluating total global vascular burden across coronary, cerebrovascular, and peripheral arterial beds
Recalibration & TRIPOD Validation Standards Assessment of calibration-in-the-large, calibration slope, and Harrell’s C-index when transporting equations to non-Framingham cohorts Adjusting baseline survival S_0(10) and mean risk factor levels (D’Agostino et al., JAMA 2001) to prevent systematic overestimation in multi-ethnic or lower-incidence populations

How Does the Framingham Risk Score Integrate with EHR and Health Informatics Workflows?

In hospital and ambulatory electronic health records (EHRs) as well as point-of-care reference platforms such as MDCalc, the Framingham Risk Score is automated by querying structured clinical data elements via HL7 Fast Healthcare Interoperability Resources (FHIR):

  • Patient & Observation Resources: Patient birthDate and administrative gender from the FHIR Patient resource; systolic blood pressure (LOINC 8480-6), serum total cholesterol (LOINC 2093-3), serum HDL cholesterol (LOINC 2085-9), and smoking status (LOINC 72166-2) from FHIR Observation resources.
  • Medication & Condition Lookup: Active antihypertensive therapy is verified from FHIR MedicationRequest or MedicationStatement resources mapped to RxNorm antihypertensive classes, while diabetes status is extracted from FHIR Condition ICD-10-CM/SNOMED CT problem lists or HbA1c observations (LOINC 4548-4).
  • Clinical Decision Support (CDS) Hooks: Using the Cox regression coefficients directly in a SMART on FHIR widget or CDS Hook service avoids rounding artifacts introduced by integer lookup tables and flags missing lipid results exceeding protocol staleness windows.

Frequently Asked Questions

What is the Framingham Risk Score and how is it used in clinical research and healthcare?

The Framingham Risk Score (FRS) is a sex-specific multivariable statistical algorithm derived from the Framingham Heart Study that estimates an asymptomatic adult’s 10-year probability of developing coronary heart disease (Wilson et al., 1998) or general cardiovascular disease (D’Agostino et al., 2008).

What standards or regulatory requirements govern the Framingham Risk Score?

The Framingham Risk Score was operationalized in the NHLBI Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III, 2001/2002) and continues to be evaluated in clinical studies alongside the 2013 ACC/AHA Pooled Cohort Equations and TRIPOD reporting standards.

How does the Framingham Risk Score integrate with EHR and health informatics workflows?

Health informatics systems integrate the Framingham Risk Score using LOINC observation codes for age, systolic blood pressure, total and HDL cholesterol, smoking status, and antihypertensive medication records via HL7 FHIR Clinical Decision Support (CDS) Hooks and SMART on FHIR applications.

Sources

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about Framingham Risk Score: 10-Year CVD Equations, Cox Regression & EHR Calculation

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →